- ICH GCP
- Yhdysvaltain kliinisten tutkimusten rekisteri
- Kliininen tutkimus NCT02492919
Medixair® System on Surgical Site Infection in Cardiac Patients
Impact of Medixair® System on Surgical Site Infection in Patients Admitted Into the Postoperative Cardiac Intensive Care Unit
There is a growing incidence of sepsis and septic shock in people after surgery, for which there may be several reasons: more elderly people and more severe illnesses are entering operating theatres, more invasive systems are being used to take care of patients in intensive care units, etc... Sepsis and septic shock are the most prevalent illnesses which cause the highest mortality in intensive care units.
The incidence of this illness is 500,000 / year in the USA, and 240-400 / 100,000 persons in Europe. So this is a subject of great interest in hospitals and also to the National Health System (to both health workers and the health authorities) as a lot of money is spent on this illness.
Since the 19th century, ultraviolet rays have been known to be able to sterilize microorganisms (to kill them); yet no ultraviolet system machine has been on the market, until now, to control nosocomial infections.
The Medixair system, which aims to do this, has recently come on to the market. It uses C-ultraviolet rays, which are the strongest kind of ultraviolet rays to kill microorganisms.
Thus, it is of interest to know whether this system is good enough to lower infections in intensive care units. It is logical to believe that the the fewer the micro-organisms, the lower the possibilities of infection.
Tutkimuksen yleiskatsaus
Yksityiskohtainen kuvaus
Study design Prospective, comparative, randomized, non intervention study
Patients
Patients older than 18 years
Cardiac Surgery anesthetized using Extracorporeal Circulation
Randomization
There are 10 independent boxes at the Postoperative Cardiac Intensive Care Unit. (Each of these boxes have single beds). Every year, the Cardiac Reanimation Unit of our hospital received 500 patients, post heart surgery.
After getting the permissions needed to make the research, the Medixair® system has been placed in 5 of these units, and the comparison group will be the other 5 beds without Medixair®. Patients have been assigned randomly to either (Medixair® and NO Medixair®).
The endpoint is:
-To compare the infection rates after a cardiac surgery, on patients located in boxes with and without a Medixair® system.
The aim is to see if there are fewer catheter infections, less bacteraemia, fewer urinary infections, less site of surgery infections, and fewer pneumonias in patients who have spent their first days after a heart surgery in a box with Medixair® system than without it. The infection rates in the intensive care unit will be followed, as well as the whole stay at hospital, as there might be fewer infections if there were fewer microorganisms around.
Other objectives are:
- Identifying preoperative, intraoperative and postoperative risk factors to develop an infection illness after cardiac surgery, as well as which increase the length of stay at hospital and the mortality rate.
- Making an economic study of using this system against not using it.
A further aim is to measure the following variables:
- Dependent variables (Outcome variables): infection
- 2º Outcome variables: colonization
- Independent variables will be a risk factor for infection:
- Preoperative: age, sex, any preoperative illness, immunosuppressor treatment, including corticosteroids.
- Intraoperative: antibiotic prophylaxis, surgical technique, length of cardiopulmonary bypass, length of aorta clamped, temperature during cardiopulmonary bypass, hematocrit at the end of cardiopulmonary bypass.
- Postoperative: length with mechanical ventilation, time spent in hospital, time spent in an intensive care unit, any organ complication (pulmonary insufficiency, renal failure, low cardiac index), septicemia, invasive techniques used, positive microorganism cultures.
All of the patients will be treated in the same way
Estimated number of patients
Nowadays, the infection rate after cardiac surgery is around 5%, so following the current hypothesis that the Medixair® system, because of its ultraviolet emissions, is going to lower the infection rate after cardiac surgery, 419 patients are needed in each group to be able to demonstrate a significative 5% reduction in infection rates, with an alpha error of 0.05 and a beta error of 0.2 to have a power of 80%.
As this is a preliminary study, in order to demonstrate a 5% reduction in the infection rate, half the number of patients (half of 419) will be used. As the patient volume is 500 a year, the number will be rounded up to 500, in order to be able to consider a complete year.
Opintotyyppi
Ilmoittautuminen (Todellinen)
Vaihe
- Ei sovellettavissa
Osallistumiskriteerit
Kelpoisuusvaatimukset
Opintokelpoiset iät
Hyväksyy terveitä vapaaehtoisia
Sukupuolet, jotka voivat opiskella
Kuvaus
Inclusion Criteria:
- Patients admitted to Postoperative Cardiac Intensive Care Unit after Cardiac Surgery with Extracorporeal Circulation
Exclusion Criteria:
- Not signing informed consent
Opintosuunnitelma
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Ensisijainen käyttötarkoitus: Tukevaa hoitoa
- Jako: Satunnaistettu
- Inventiomalli: Rinnakkaistehtävä
- Naamiointi: Ei mitään (avoin tarra)
Aseet ja interventiot
Osallistujaryhmä / Arm |
Interventio / Hoito |
---|---|
Kokeellinen: Medixair®
Cardiac reanimation unit bed with Medixair®
|
Medixair system uses C-ultraviolet rays, which are the strongest ultraviolet kind of rays to kill microorganisms.
The intervention consist consists of adding the Medixair® device, to be various beds of Cardiac Reanimation Units, or not.
|
Ei väliintuloa: NO Medixair®
Cardiac reanimation unit bed with NO Medixair®
|
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
---|---|---|
Infection rates after cardiac surgery
Aikaikkuna: 3 weeks
|
To assess if there are fewer catheter infections, less bacteraemia, fewer urinary infections, fewer surgery site infections, fewer pneumonias in patients who have spent their first days after a heart surgery in a box with the Medixair system than without it.
|
3 weeks
|
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
---|---|---|
Number of infected patients
Aikaikkuna: 3 weeks
|
Number of infected patients
|
3 weeks
|
mortality rate
Aikaikkuna: 3 weeks and for the whole stay at hospital
|
mortality rate
|
3 weeks and for the whole stay at hospital
|
number of patients with pneumonia
Aikaikkuna: 3 weeks
|
number of patients with pneumonia
|
3 weeks
|
Yhteistyökumppanit ja tutkijat
Sponsori
Yhteistyökumppanit
Tutkijat
- Opintojohtaja: Eduardo Tamayo, PhD, MD, Hospital Clínico Universitario de Valladolid
Opintojen ennätyspäivät
Opi tärkeimmät päivämäärät
Opiskelun aloitus
Ensisijainen valmistuminen (Todellinen)
Opintojen valmistuminen (Todellinen)
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen Lähetetty (Arvio)
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Arvio)
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeksi vahvistettu
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Avainsanat
Muita asiaankuuluvia MeSH-ehtoja
Muut tutkimustunnusnumerot
- PI 14-176
- 17-01-2011 (Muu tunniste: Comision Investigacion HCUV)
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .
Kliiniset tutkimukset Leikkausalueen infektio
-
Becton, Dickinson and CompanyValmisKatetriin liittyvä komplikaatio | Vascular Access Site Management | Desinfioiva korkkiBelgia, Itävalta, Espanja, Italia
-
Medstar Health Research InstituteCardinal HealthValmisSydämen diagnostinen menettely | Sydämen interventiomenettely | Femoral Access Site sulkeminenYhdysvallat
-
Universitätsmedizin MannheimValmisPerkutaaninen sepelvaltimon interventio (PCI) | Valtimonsulkulaite | Access Site Bleeding | Haitalliset sydäntapahtumatSaksa
-
EarlySense Ltd.PeruutettuPost Surgical Pat., Medical Pat., Resp. Epäonnistuminen, auto. Pidätys, kuolemaYhdysvallat
-
The Affiliated Nanjing Drum Tower Hospital of Nanjing...RekrytointiStoma Site Incisional herniaKiina
-
National Healthcare Group, SingaporeValmisHemodialyysin komplikaatio | Fisteli | Verisuonten pääsyn komplikaatio | Dialyysi; Komplikaatiot | Vascular Access Site Hematooma | Dialyysin käyttöhäiriö | Graft AvSingapore
Kliiniset tutkimukset Medixair®
-
Galderma R&DValmisAtooppinen ihottumaFilippiinit, Kiina
-
Dong-A ST Co., Ltd.ValmisFunktionaalinen dyspepsiaKorean tasavalta
-
Amir AzarpazhoohInstitut Straumann AGValmisParodontaalin tulehdus | Kruunun pidennysKanada
-
Novartis PharmaceuticalsValmisKeuhkosairaus, krooninen obstruktiivinen (COPD)Argentiina
-
GuerbetValmisPrimaarinen aivokasvainKolumbia, Korean tasavalta, Yhdysvallat, Meksiko
-
Chong Kun Dang PharmaceuticalValmis
-
Chung-Ang University Hosptial, Chung-Ang University...TuntematonFunktionaalinen dyspepsiaKorean tasavalta
-
University of MiamiBSN Medical IncRekrytointi
-
Sanofi Pasteur, a Sanofi CompanyValmisPertussis | Kurkkumätä | PolioYhdysvallat
-
Sanofi Pasteur, a Sanofi CompanyValmis